A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy?
Background. Since neoadjuvant treatment in esophageal cancer began to become popular, a complete pathological response at the primary tumour site has been commonly reported. An issue of conflict is whether complete response in the esophageal lumen means that the esophagus is completely tumour-free....
Saved in:
Main Authors: | Sebahattin Celik, Remzi Erten, Abdulsamed Batur, Burak Suvak |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Case Reports in Pathology |
Online Access: | http://dx.doi.org/10.1155/2015/158626 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for stage II–IVa esophageal cancer: a network meta-analysis
by: Mingxing Wang, et al.
Published: (2025-01-01) -
Neoadjuvant Chemoradiotherapy Upregulates the Immunogenicity of Cold to Hot Tumors in Esophageal Cancer Patients
by: Yushi Nagaki, MD, PhD, et al.
Published: (2024-03-01) -
Tumor Size as a Critical Prognostic Factor in T1-2 Stage Esophageal Cancer
by: Zilong Wu, et al.
Published: (2020-01-01) -
Esophageal Varices: Pathophysiology, Approach, and Clinical Dilemmas
by: Nir Hilzenrat, et al.
Published: (2012-01-01) -
Staging of esophageal cancer using PET/MRI: a systematic review with head-to-head comparison
by: Alisa Mohebbi, et al.
Published: (2025-01-01)